Rogalsky V Y, Koven I H, Miller D R, Pollard A
Cancer Detect Prev. 1985;8(4):477-83.
The macrocreatine kinase type 2 isoenzyme (MCK-2) was investigated as a marker for colonic cancer. It was sought in 252 serum samples from 231 patients: 69 with active colonic cancer, 49 in whom colonic cancer had been successfully resected, 58 with nonmalignant diseases of the colon, and 76 patients immediately following colonic surgery. MCK-2 was detected in the serum of 39 of the patients with cancer (57%) and in one patient with diverticulitis. MCK-2 and carcinoembryonic antigen (CEA) were both measured in 47 colonic cancer patients. Both markers were detected in 19 cases, MCK-2 alone in eight and CEA alone in eight. We conclude that MCK-2 is a promising tumor marker for carcinoma of the colon and that its value might be complementary to that of CEA.
对2型巨肌酸激酶同工酶（MCK - 2）作为结肠癌标志物进行了研究。在来自231例患者的252份血清样本中进行了检测：69例患有活动性结肠癌，49例结肠癌已成功切除，58例患有结肠非恶性疾病，76例为结肠手术后即刻的患者。在39例癌症患者（57%）的血清中检测到MCK - 2，在1例憩室炎患者中也检测到MCK - 2。对47例结肠癌患者同时检测了MCK - 2和癌胚抗原（CEA）。两种标志物均在19例中检测到，仅MCK - 2在8例中检测到，仅CEA在8例中检测到。我们得出结论，MCK - 2是一种有前景的结肠癌肿瘤标志物，其价值可能与CEA互补。
